3 recruiting, 1 not yet recruiting. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Recruiting 3, Not yet recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Wuhan Createrna Science and Technology Co., Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension QR12000 75mg, QR12000 75mg placebo, QR12000 150mg - Essential Hypertension | Phase 3 | Not yet recruiting | Wuhan Createrna Science and Technology Co., Ltd | 810 | 2024-12-30 | 2024-12-06 |
| Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria MY008211A tablets - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 / Phase 3 | Recruiting | Wuhan Createrna Science and Technology Co., Ltd | 120 | 2024-11-30 | 2025-04-18 |
| Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment MY008211A tablets - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Recruiting | Wuhan Createrna Science and Technology Co., Ltd | 20 | 2024-08-30 | 2025-05-09 |
| Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy MY008211A tablets, Eculizumab Injection - Paroxysmal Nocturnal Haemoglobinuria (PNH) | Phase 3 | Recruiting | Wuhan Createrna Science and Technology Co., Ltd | 66 | 2024-08-30 | 2025-05-09 |
Hemoglobinuria, Paroxysmal (3) · Essential Hypertension (1)
Valsartan (1) · eculizumab (1) · sacubitril (1)
China (4)